22 active not recruiting, 16 recruiting, 9 completed, 9 terminated. 42 Phase 2, 38 Phase 1, 10 Phase 3.
Follow belantamab mafodotin: new trials by email Literature Review of belantamab mafodotin trials Research Report on belantamab mafodotin
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of Belantamab Mafodotin, Cevostamab, Pomalidomide for RRMM Patients (MAPLE) Belamaf, Cevostamab, Pomalidomide - Relapsed Refractory Multiple Myeloma (RRMM) | Phase 1 | Not yet recruiting | Canadian Myeloma Research Group | 108 | 2026-12-01 | 2026-09-21 |
| A Collaborative Community Effort Using Belantamab Mafodotin in Relapsed/Refractory Myeloma Belantamab mafodotin - Relapsed/Refractory Multiple Myeloma | Phase 2 | Withdrawn | Cristiana Costa Chase, DO | 2026-11-01 | 2026-09-28 | |
| A Study of the Combination of Belantamab Mafodotin, Bortezomib, and Dexamethasone (BVd) in Participants With Multiple Myeloma and Moderate Hepatic Impairment Belantamab mafodotin, Bortezomib, Dexamethasone - Multiple Myeloma | Phase 1 | Not yet recruiting | GlaxoSmithKline | 20 | 2026-10-23 | 2026-05-27 |
| Comparing Lower Versus Standard Doses of Belantamab Mafodotin With Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma. Belantamab Mafodotin, Pomalidomide, Dexamethasone - Relapsed / Refractory Multiple Myeloma | Phase 2 | Not yet recruiting | Polish Myeloma Consortium | 228 | 2026-10-01 | 2026-08-06 |
| Belantamab Mafodotin or Daratumumab With Bortezomib, Lenalidomide and Dexamethasone for Newly Diagnosed Multiple Myeloma Arm A: Belantamab Mafodotin, Arm B: Daratumumab Hyaluronidase, Bortezomib - Multiple Myeloma | Phase 3 | Recruiting | PrECOG, LLC. | 500 | 2026-09-01 | 2026-08-17 |
| TAlquetamab and BeLantamab Mafodotin in Relapsed/Refractory Multiple Myeloma (TaBleMM) Talquetamab, Belantamab mafodotin, Pomalidomide - Relapse Multiple Myeloma, Refractory Multiple Myeloma | Phase 1 | Not yet recruiting | Montefiore Medical Center | 50 | 2026-09-01 | 2026-07-22 |
| Study of Alternative and Approved Dosing Regimens of Belantamab Mafodotin, Bortezomib, and Dexamethasone (BVd) in Participants With Relapsed/Refractory Multiple Myeloma Belantamab mafodotin, Dexamethasone, Bortezomib - Multiple Myeloma | Phase 2 | Not yet recruiting | GlaxoSmithKline | 150 | 2026-08-03 | 2026-06-24 |
| A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Cyclophosphamide, Bortezomib, and Dexamethasone in Adult Participants With Newly Diagnosed Amyloid Light Chain (AL) Amyloidosis Belantamab mafodotin, Cyclophosphamide, Bortezomib - Amyloidosis | Phase 2 | Recruiting | GlaxoSmithKline | 60 | 2026-06-24 | 2026-07-17 |
| Study to Evaluate Efficacy and Safety of Belantamab-based Combinations for Relapsed Multiple Myeloma Belantamab mafodotin, Bortezomib, Dexamethasone - Relapse Multiple Myeloma | Not yet recruiting | PETHEMA Foundation | 100 | 2026-06-01 | 2026-06-24 | |
| A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Standard of Care in Participants With Relapsed-Refractory Multiple Myeloma (RRMM) Belantamab mafodotin, Dexamethasone, Pomalidomide - Multiple Myeloma | Phase 2 | Recruiting | GlaxoSmithKline | 200 | 2026-04-15 | 2026-08-25 |
| A PHASE II TRIAL AIMING TO INVESTIGATE THE SAFETY AND CLINICAL ACTIVITY OF BELANTAMAB MAFODOTIN IN ADULT PATIENTS WITH PRIMARY IMMUNE THROMBOCYTOPENIA PREVIOUSLY TREATED WITH A THROMBOPOIETIN RECEPTOR AGONIST AND/OR RITUXIMAB AFTER CORTICOSTEROID FIRST-LINE THERAPY Belantamab Mafodotin, Dexamethasone - Primary Immune Thrombocytopenia (ITP) | Phase 2 | Not yet recruiting | Hellenic Society of Hematology | 14 | 2025-06-20 | 2025-06-13 |
| Testing the Combination of Two Approved Drugs and One Experimental Drug in Patients With Relapsed or Refractory Multiple Myeloma Iberdomide, Belantamab Mafodotin, Dexamethasone - Recurrent Multiple Myeloma, Refractory Multiple Myeloma | Phase 1 / Phase 2 | Suspended | Alliance for Clinical Trials in Oncology | 88 | 2025-04-23 | 2026-10-02 |
| A Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Who Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM) Belantamab mafodotin, Lenalidomide, Dexamethasone - Multiple Myeloma, Newly Diagnosed Multiple Myeloma | Phase 3 | Recruiting | GlaxoSmithKline | 520 | 2024-12-16 | 2026-04-22 |
| Belantamab Mafodotin and Lenalidomide for the Treatment of Multiple Myeloma in Patients With Minimal Residual Disease Positive After Stem Cell Transplant Belantamab Mafodotin, Lenalidomide - Plasma Cell Myeloma | Phase 2 | Active not recruiting | Roswell Park Cancer Institute | 4 | 2024-08-19 | 2026-10-16 |
| A Study to Investigate the Safety and Pharmacological Effect of a Single Intravenous Infusion of Belantamab in Male and Female Participants Aged 18 to 75 With Autoimmune Disease Belantamab - Autoimmune Diseases | Phase 1 | Withdrawn | GlaxoSmithKline | 2024-06-03 | 2025-08-27 | |
| Isatuximab, Bela Maf, Pom, and Dex in Relapsed/Refractory Multiple Myeloma Isatuximab, Belantamab mafodotin, Pomalidomide - Relapsed Cancer, Refractory Multiple Myeloma | Phase 2 | Recruiting | Massachusetts General Hospital | 50 | 2024-05-31 | 2026-01-14 |
| Phase 1/2a Study of Belantamab Mafodotin in Relapsed or Refractory AL Amyloidosis Belantamab mafodotin 2.5 mg/kg (8 weeks), Belantamab mafodotin 1.9 mg/kg (8 weeks), Belantamab mafodotin 1.4 mg/kg (12 weeks) - AL Amyloidosis, Amyloidosis | Phase 1 / Phase 2 | Recruiting | University of Texas Southwestern Medical Center | 37 | 2024-02-15 | 2026-08-19 |
| Alternate Doses and Dosing Schedules of Belantamab Mafodotin for Treatment of Triple-Class Refractory Multiple Myeloma Belantamab Mafodotin, Biospecimen Collection, Bone Marrow Aspirate - Recurrent Multiple Myeloma, Refractory Multiple Myeloma | Phase 2 | Recruiting | Mayo Clinic | 62 | 2024-01-04 | 2026-07-14 |
| Combination Treatment of Belantamab Mafodotin and Venetoclax in Treatment of Relapsed and Refractory t(11;14) Multiple Myeloma Belantamab mafodotin, Venetoclax - Multiple Myeloma, Multiple Myeloma in Relapse | Phase 1 / Phase 2 | Recruiting | Universitätsklinikum Hamburg-Eppendorf | 45 | 2023-06-28 | 2026-05-18 |
| A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments Belantamab, Belantamab mafodotin, Pomalidomide - Multiple Myeloma | Phase 1 / Phase 2 | Recruiting | GlaxoSmithKline | 123 | 2023-06-14 | 2026-08-19 |
Showing 20 of 71. Sign in to see all of them.
Multiple Myeloma (58) · Recurrence (5) · Neoplasms, Plasma Cell (4) · Immunoglobulin Light-chain Amyloidosis (3) · Amyloidosis (2) · Neoplasm, Residual (2) · Autoimmune Diseases (1) · Corneal Diseases (1) · Kidney Failure, Chronic (1) · Lupus Erythematosus, Systemic (1) · Plasmablastic Lymphoma (1) · Purpura, Thrombocytopenic, Idiopathic (1) · Renal Insufficiency (1)
GlaxoSmithKline (32) · PETHEMA Foundation (4) · M.D. Anderson Cancer Center (3) · Canadian Myeloma Research Group (2) · Hellenic Society of Hematology (2) · Mayo Clinic (2) · Alliance for Clinical Trials in Oncology (1) · Cristiana Costa Chase, DO (1) · Emory University (1) · Fondazione EMN Italy Onlus (1) · Hackensack Meridian Health (1) · Jacob Soumerai, MD (1) · Janssen Research & Development, LLC (1) · Karyopharm Therapeutics Inc (1) · Massachusetts General Hospital (1)
United States (44) · Canada (17) · South Korea (17) · Greece (16) · Spain (16) · France (15) · Australia (14) · Germany (14) · Poland (11) · Brazil (9) · Italy (9) · Japan (9) · United Kingdom (9) · China (7) · Netherlands (7)
Javier de la Rubia (2) · Adam Cohen, MD (1) · Ajay K. Nooka, MD,MPH,FACP (1) · Andrew Yee, MD (1) · Ashraf Badros, MB; ChB (1) · Benjamin Derman, MD (1) · Cristiana Costa Chase, DO (1) · David R Levitz, MD (1) · Hearn J Cho, M.D., Ph.D. (1) · Jacob Soumerai, MD (1) · Jens Hillengass (1)
PMID 35285981, PMID 40763276, PMID 21799510, PMID 26370838, PMID 30352784, PMID 30442502, PMID 31859245, PMID 33682447, PMID 33730360, PMID 34182226, PMID 37393120, PMID 37465991, PMID 37793771, PMID 38177852, PMID 38270219, PMID 38630908, PMID 38826786, PMID 38828933, PMID 38828951, PMID 40338596, PMID 40680752, PMID 40680754, PMID 40958065, PMID 41193117, PMID 41346230, PMID 41719502, PMID 42726457, PMID 42786443
2023 (11), 2018 (3), 2025 (3), 2019 (2), 2017 (1), P30CA138292 (1)